RCEL · Avita Medical Inc. Common Stock
View on chartInsiders & Stakes
| Michael S. Perry Chief Executive Officer | ▼ Sell | Open Market | 229,543 Shares held | 11/21/2022 | View profile |
| David D. O'Toole CFO | ▲ Buy | Grant | 152,927 Shares held | 6/12/2026 | View profile |
| Robert McNamara Director | ▲ Buy | Grant | 108,985 Shares held | 1/20/2026 | View profile |
| Joseph Fralin Woody | ▲ Buy | Open Market | 102,761 Shares held | 6/9/2026 | View profile |
| Nicole Kelsey Chief Legal Officer | ▲ Buy | Grant | 98,390 Shares held | 2/18/2026 | View profile |
| Jan Stern Reed Director | ▲ Buy | Grant | 73,225 Shares held | 1/20/2026 | View profile |
| Suzanne Crowe Director | ▲ Buy | Grant | 69,148 Shares held | 1/20/2026 | View profile |
| Jeremy Curnock Cook Director | ▲ Buy | Grant | 62,050 Shares held | 1/20/2026 | View profile |
| Lou Panaccio Director | ▲ Buy | Grant | 56,428 Shares held | 1/21/2025 | View profile |
| Michael E. Tarnoff Director | ▲ Buy | Grant | 48,464 Shares held | 1/20/2026 | View profile |
| Michael Holder Chief Financial Officer | ▲ Buy | Grant | 46,450 Shares held | 7/1/2022 | View profile |
| Liberto Erin Chief Commercial Officer | ▲ Buy | Grant | 46,450 Shares held | 7/1/2022 | View profile |
| McGee Kathy M. Chief Operating Officer | ▲ Buy | Grant | 46,450 Shares held | 7/1/2022 | View profile |
| Quick Andrew Chief Technology Officer | ▲ Buy | Grant | 46,450 Shares held | 7/1/2022 | View profile |
| Shiroma Donna General Counsel | ▲ Buy | Grant | 45,951 Shares held | 5/31/2024 | View profile |
| Cary Guy Vance Director | ▲ Buy | Grant | 40,771 Shares held | 5/29/2026 | View profile |
| CORBETT JAMES Director | ▼ Sell | Open Market | 11,580 Shares held | 12/26/2023 | View profile |
| Drapeau Louis Director | ▲ Buy | Grant | 4,689 Shares held | 12/22/2021 | View profile |
Transaction History
| David D. O'Toole | ▲ Buy | Grant | 2,000 | $8K | 6/12/2026 |
| Joseph Fralin Woody | ▲ Buy | Open Market | 5,200 | $21K | 6/9/2026 |
| Joseph Fralin Woody | ▲ Buy | Open Market | 5,000 | $21K | 6/9/2026 |
| Joseph Fralin Woody | ▲ Buy | Open Market | 5,000 | $21K | 6/9/2026 |
| Joseph Fralin Woody | ▲ Buy | Open Market | 5,000 | $20K | 6/3/2026 |
| Joseph Fralin Woody | ▲ Buy | Open Market | 5,000 | $20K | 6/3/2026 |
| Joseph Fralin Woody | ▲ Buy | Open Market | 5,000 | $21K | 6/2/2026 |
| Joseph Fralin Woody | ▲ Buy | Open Market | 5,000 | $21K | 6/2/2026 |
| Joseph Fralin Woody | ▲ Buy | Open Market | 5,000 | $22K | 6/1/2026 |
| Joseph Fralin Woody | ▲ Buy | Open Market | 5,000 | $21K | 6/1/2026 |
| David D. O'Toole | ▲ Buy | Grant | 5,000 | $15K | 5/29/2026 |
| Cary Guy Vance | ▲ Buy | Grant | 5,000 | $15K | 5/29/2026 |
| David D. O'Toole | ▲ Buy | Open Market | 2,000 | $9K | 5/20/2026 |
| David D. O'Toole | ▲ Buy | Open Market | 2,000 | $8K | 5/19/2026 |
| David D. O'Toole | ▲ Buy | Open Market | 1,800 | $9K | 3/11/2026 |
| David D. O'Toole | ▲ Buy | Open Market | 3,000 | $12K | 2/19/2026 |
| Nicole Kelsey | ▲ Buy | Grant | 98,390 | — | 2/18/2026 |
| David D. O'Toole | ▲ Buy | Grant | 105,470 | — | 2/18/2026 |
| Joseph Fralin Woody | ▲ Buy | Grant | 22,214 | — | 1/20/2026 |
| Robert McNamara | ▲ Buy | Grant | 22,214 | — | 1/20/2026 |
| Michael E. Tarnoff | ▲ Buy | Grant | 22,214 | — | 1/20/2026 |
| Jeremy Curnock Cook | ▲ Buy | Grant | 22,214 | — | 1/20/2026 |
| Jan Stern Reed | ▲ Buy | Grant | 22,214 | — | 1/20/2026 |
| Suzanne Crowe | ▲ Buy | Grant | 22,214 | — | 1/20/2026 |
| Joseph Fralin Woody | ▲ Buy | Grant | 40,547 | — | 1/5/2026 |
| Robert McNamara | ▲ Buy | Open Market | 10,000 | $45K | 8/28/2025 |
| David D. O'Toole | ▲ Buy | Open Market | 2,000 | $9K | 8/26/2025 |
| Robert McNamara | ▲ Buy | Open Market | 10,000 | $50K | 8/19/2025 |
| David D. O'Toole | ▲ Buy | Open Market | 2,000 | $10K | 8/12/2025 |
| Michael E. Tarnoff | ▲ Buy | Grant | 26,250 | — | 8/6/2025 |
| David D. O'Toole | ▲ Buy | Grant | 1,923 | $9K | 5/30/2025 |
| Robert McNamara | ▲ Buy | Open Market | 11,000 | $91K | 3/6/2025 |
| Robert McNamara | ▲ Buy | Open Market | 10,000 | $101K | 2/20/2025 |
| David D. O'Toole | ▲ Buy | Open Market | 1,000 | $10K | 2/20/2025 |
| David D. O'Toole | ▲ Buy | Open Market | 1,000 | $10K | 2/19/2025 |
| Suzanne Crowe | ▲ Buy | Grant | 10,022 | — | 1/21/2025 |
| Jan Stern Reed | ▲ Buy | Grant | 10,022 | — | 1/21/2025 |
| Robert McNamara | ▲ Buy | Grant | 10,022 | — | 1/21/2025 |
| Lou Panaccio | ▲ Buy | Grant | 10,022 | — | 1/21/2025 |
| Jeremy Curnock Cook | ▲ Buy | Grant | 10,022 | — | 1/21/2025 |
| Cary Guy Vance | ▲ Buy | Grant | 10,022 | — | 1/21/2025 |
| Suzanne Crowe | ▲ Buy | Open Market | 486 | $6K | 12/9/2024 |
| David D. O'Toole | ▲ Buy | Open Market | 475 | $6K | 12/5/2024 |
| David D. O'Toole | ▲ Buy | Open Market | 500 | $6K | 12/5/2024 |
| David D. O'Toole | ▲ Buy | Grant | 785 | $6K | 11/29/2024 |
| Robert McNamara | ▲ Buy | Grant | 10,000 | $90K | 8/19/2024 |
| Lou Panaccio | ▲ Buy | Grant | 9,200 | — | 6/5/2024 |
| Suzanne Crowe | ▲ Buy | Grant | 9,200 | — | 6/5/2024 |
| Jeremy Curnock Cook | ▲ Buy | Grant | 9,200 | — | 6/5/2024 |
| Jan Stern Reed | ▲ Buy | Grant | 9,200 | — | 6/5/2024 |
| Robert McNamara | ▲ Buy | Grant | 9,200 | — | 6/5/2024 |
| Cary Guy Vance | ▲ Buy | Grant | 9,200 | — | 6/5/2024 |
| Shiroma Donna | ▲ Buy | Grant | 2,225 | $18K | 5/31/2024 |
| David D. O'Toole | ▲ Buy | Grant | 2,240 | $18K | 5/31/2024 |
| David D. O'Toole | ▲ Buy | Open Market | 500 | $5K | 5/30/2024 |
| David D. O'Toole | ▲ Buy | Open Market | 500 | $4K | 5/30/2024 |
| David D. O'Toole | ▲ Buy | Open Market | 1,000 | $17K | 2/28/2024 |
| David D. O'Toole | ▲ Buy | Open Market | 250 | $4K | 2/28/2024 |
| CORBETT JAMES | ▼ Sell | Open Market | 1,445 | $19K | 12/26/2023 |
| Jeremy Curnock Cook | ▼ Sell | Open Market | 2,518 | $31K | 12/13/2023 |
| David D. O'Toole | ▲ Buy | Open Market | 950 | $12K | 12/12/2023 |
| David D. O'Toole | ▲ Buy | Open Market | 500 | $5K | 12/1/2023 |
| Shiroma Donna | ▲ Buy | Grant | 1,469 | $13K | 11/30/2023 |
| David D. O'Toole | ▲ Buy | Grant | 1,034 | $9K | 11/30/2023 |
| David D. O'Toole | ▲ Buy | Open Market | 1,000 | $10K | 11/21/2023 |
| David D. O'Toole | ▲ Buy | Open Market | 1,000 | $10K | 11/21/2023 |
| David D. O'Toole | ▲ Buy | Open Market | 1,000 | $12K | 11/16/2023 |
| David D. O'Toole | ▲ Buy | Open Market | 1,000 | $12K | 11/15/2023 |
| David D. O'Toole | ▲ Buy | Open Market | 1,000 | $13K | 11/15/2023 |
| David D. O'Toole | ▲ Buy | Open Market | 1,000 | $13K | 11/14/2023 |
| Shiroma Donna | ▼ Sell | Open Market | 4,193 | $66K | 8/21/2023 |
| David D. O'Toole | ▲ Buy | Open Market | 1,000 | $17K | 8/16/2023 |
| David D. O'Toole | ▲ Buy | Open Market | 1,000 | $17K | 8/16/2023 |
| David D. O'Toole | ▲ Buy | Open Market | 1,000 | $18K | 8/15/2023 |
| David D. O'Toole | ▲ Buy | Open Market | 1,000 | $18K | 8/15/2023 |
| David D. O'Toole | ▲ Buy | Open Market | 1,000 | $18K | 8/15/2023 |
| David D. O'Toole | ▲ Buy | Open Market | 1,000 | $18K | 8/15/2023 |
| David D. O'Toole | ▲ Buy | Open Market | 1,000 | $18K | 8/15/2023 |
| David D. O'Toole | ▲ Buy | Open Market | 1,000 | $16K | 6/20/2023 |
| Robert McNamara | ▲ Buy | Grant | 6,175 | — | 6/6/2023 |
| Jeremy Curnock Cook | ▲ Buy | Grant | 6,175 | — | 6/6/2023 |
| Suzanne Crowe | ▲ Buy | Grant | 6,175 | — | 6/6/2023 |
| Robert McNamara | ▲ Buy | Grant | 10,374 | — | 6/6/2023 |
| Lou Panaccio | ▲ Buy | Grant | 6,175 | — | 6/6/2023 |
| Cary Guy Vance | ▲ Buy | Grant | 6,175 | — | 6/6/2023 |
| Jan Stern Reed | ▲ Buy | Grant | 6,175 | — | 6/6/2023 |
| Cary Guy Vance | ▲ Buy | Grant | 10,374 | — | 6/6/2023 |
| Jeremy Curnock Cook | ▲ Buy | Grant | 12,589 | — | 12/12/2022 |
| Suzanne Crowe | ▲ Buy | Grant | 12,589 | — | 12/12/2022 |
| Lou Panaccio | ▲ Buy | Grant | 12,589 | — | 12/12/2022 |
| Jan Stern Reed | ▲ Buy | Grant | 12,589 | — | 12/12/2022 |
| Michael S. Perry | ▲ Buy | Option Exercise | 150,000 | $899K | 11/21/2022 |
| Michael S. Perry | ▼ Sell | Open Market | 150,000 | $1.1M | 11/21/2022 |
| Michael S. Perry | ▲ Buy | Grant | 2,980 | $0 | 9/1/2022 |
| Liberto Erin | ▲ Buy | Grant | 35,950 | — | 7/1/2022 |
| Quick Andrew | ▲ Buy | Grant | 35,950 | — | 7/1/2022 |
| McGee Kathy M. | ▲ Buy | Grant | 35,950 | — | 7/1/2022 |
| Michael Holder | ▲ Buy | Grant | 35,950 | — | 7/1/2022 |
| Shiroma Donna | ▲ Buy | Grant | 35,950 | — | 7/1/2022 |
| Michael S. Perry | ▼ Sell | Other | 23,754 | $0 | 6/1/2022 |
| Michael S. Perry | ▼ Sell | Open Market | 10,812 | $94K | 2/24/2022 |
| Michael S. Perry | ▲ Buy | Grant | 5,960 | $0 | 2/23/2022 |
| Michael S. Perry | ▲ Buy | Grant | 23,753 | $0 | 2/23/2022 |
| Suzanne Crowe | ▲ Buy | Grant | 4,350 | — | 12/22/2021 |
| Drapeau Louis | ▲ Buy | Grant | 4,350 | — | 12/22/2021 |
| Michael S. Perry | ▲ Buy | Grant | 23,820 | — | 12/22/2021 |
| Michael S. Perry | ▲ Buy | Grant | 23,820 | — | 12/22/2021 |
| Jeremy Curnock Cook | ▲ Buy | Grant | 4,350 | — | 12/22/2021 |
| CORBETT JAMES | ▲ Buy | Grant | 8,675 | — | 12/22/2021 |
| CORBETT JAMES | ▲ Buy | Grant | 4,350 | — | 12/22/2021 |
| Jan Stern Reed | ▲ Buy | Grant | 4,350 | — | 12/22/2021 |
| Jan Stern Reed | ▲ Buy | Grant | 8,675 | — | 12/22/2021 |
| Lou Panaccio | ▲ Buy | Grant | 4,350 | — | 12/22/2021 |
| Michael S. Perry | ▲ Buy | Grant | 23,800 | — | 12/22/2021 |
| Suzanne Crowe | ▲ Buy | Open Market | 1,066 | $18K | 9/20/2021 |
| Michael S. Perry | ▼ Sell | Open Market | 11,220 | $232K | 9/1/2021 |
| Michael S. Perry | ▲ Buy | Grant | 23,754 | $0 | 9/1/2021 |
| Quick Andrew | ▲ Buy | Grant | 10,500 | — | 7/6/2021 |
| Shiroma Donna | ▲ Buy | Grant | 10,500 | — | 7/6/2021 |
| Michael Holder | ▲ Buy | Grant | 10,500 | — | 7/6/2021 |
| Liberto Erin | ▲ Buy | Grant | 10,500 | — | 7/6/2021 |
| McGee Kathy M. | ▲ Buy | Grant | 10,500 | — | 7/6/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
RCEL Gains Fair Value Lift After PermeaDerm Data and Q2 Beat
PermeaDerm data and a Q2 earnings beat lifted RCEL’s fair value. The news gave the stock a positive momentum boost. The lift comes as the company reports stronger‑than‑expected results and promising data from its PermeaDerm platform. The move is a short‑term reaction to the earnings beat and data release.
RCEL Gains Fair Value Lift After PermeaDerm Data and Q2 Beat. PermeaDerm data and a Q2 earnings beat lifted RCEL’s fair value. The news gave the stock a positive momentum boost. The lift comes as the company reports stronger‑than‑expected results and promising data from its PermeaDerm platform. The move is a short‑term reaction to the earnings beat and data release.